Alzheimer's disease pathology is attenuated in a CD38-deficient mouse model

Annals of Neurology

Volumn 78, Issue 1, 2015, Pages 88-103

  Blacher, Eran ^a   Dadali, Tulin ^b   Bespalko, Alina ^a   Haupenthal, Viola J ^c   Grimm, Marcus O W ^c   Hartmann, Tobias ^c   Lund, Frances E ^b   Stein, Reuven ^a   Levy, Ayelet ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b University of Alabama at Birmingham   (United States)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; GAMMA SECRETASE; GLYCOSIDASE INHIBITOR; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE NUCLEOSIDASE; SYNAPTOPHYSIN; AMYLOID BETA PROTEIN; CD38 ANTIGEN; CD38 PROTEIN, MOUSE; MEMBRANE PROTEIN; SECRETASE; TRANSCRIPTOME;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HEMISPHERE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MICROGLIA; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NERVE CELL CULTURE; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; REAL TIME POLYMERASE CHAIN REACTION; SPATIAL LEARNING; ANIMAL; ANIMAL BEHAVIOR; BRAIN; CELL CULTURE; CELL MOTION; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIGENS, CD38; BEHAVIOR, ANIMAL; BRAIN; CELL MOVEMENT; CELLS, CULTURED; DISEASE MODELS, ANIMAL; MACROPHAGES; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROGLIA; PLAQUE, AMYLOID; RNA, MESSENGER; SPATIAL LEARNING; TRANSCRIPTOME;

EID: 84933180740     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24425     Document Type: Article

References (46)

1. Serrano-Pozo A, Frosch MP, Masliah E, et al., Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1: a006189.
2. O'Brien RJ, Wong PC,. Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci 2011; 34: 185-204.
3. Itagaki S, McGeer PL, Akiyama H, et al., Relationship of microglia and astrocytes to amyloid deposits of Alzheimer disease. J Neuroimmunol 1989; 24: 173-182.
4. El Khoury J, Toft M, Hickman SE, et al., Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007; 13: 432-438.
5. Kettenmann H, Hanisch UK, Noda M, et al., Physiology of microglia. Physiol Rev 2011; 91: 461-553.
6. Aksoy P, White TA, Thompson M, et al., Regulation of intracellular levels of NAD: a novel role for CD38. Biochem Biophys Res Commun 2006; 345: 1386-1392.
7. Young GS, Choleris E, Lund FE, et al., Decreased cADPR and increased NAD+ in the Cd38-/- mouse. Biochem Biophys Res Commun 2006; 346: 188-192.
8. Chini EN,. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr Pharm Des 2009; 15: 57-63.
9. Aksoy P, Escande C, White TA, et al., Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. Biochem Biophysical Res Commun 2006; 349: 353-359.
10. Partida-Sanchez S, Goodrich S, Kusser K, et al., Regulation of dendritic cell trafficking by the ADP-ribosyl cyclase CD38: impact on the development of humoral immunity. Immunity 2004; 20: 279-291.
11. Mayo L, Jacob-Hirsch J, Amariglio N, et al., Dual role of CD38 in microglial activation and activation-induced cell death. J Immunol 2008; 181: 92-103.
12. Mizuguchi M, Otsuka N, Sato M, et al., Neuronal localization of CD38 antigen in the human brain. Brain Res 1995; 697: 235-240.
13. Banerjee S, Walseth TF, Borgmann K, et al., CD38/cyclic ADP-ribose regulates astrocyte calcium signaling: implications for neuroinflammation and HIV-1-associated dementia. J Neuroimmune Pharmacol 2008; 3: 154-164.
14. Higashida H, Bowden SE, Yokoyama S, et al., Overexpression of human CD38/ADP-ribosyl cyclase enhances acetylcholine-induced Ca2+ signalling in rodent NG108-15 neuroblastoma cells. Neurosci Res 2007; 57: 339-346.
15. Bruzzone S, Verderio C, Schenk U, et al., Glutamate-mediated overexpression of CD38 in astrocytes cultured with neurones. J Neurochem 2004; 89: 264-272.
16. Verderio C, Bruzzone S, Zocchi E, et al., Evidence of a role for cyclic ADP-ribose in calcium signalling and neurotransmitter release in cultured astrocytes. J Neurochem 2001; 78: 646-657.
17. Franco L, Bodrato N, Moreschi I, et al., Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated activation of murine N9 microglial cell line. J Neurochem 2006; 99: 165-176.
18. Partida-Sanchez S, Iribarren P, Moreno-Garcia ME, et al., Chemotaxis and calcium responses of phagocytes to formyl peptide receptor ligands is differentially regulated by cyclic ADP ribose. J Immunol 2004; 172: 1896-1906.
19. Levy A, Bercovich-Kinori A, Alexandrovich AG, et al., CD38 facilitates recovery from traumatic brain injury. J Neurotrauma 2009; 26: 1521-1533.
20. Jankowsky JL, Fadale DJ, Anderson J, et al., Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-170.
21. Cockayne DA, Muchamuel T, Grimaldi JC, et al., Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood 1998; 92: 1324-1333.
22. Levy A, Blacher E, Vaknine H, et al., CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages. Neuro Oncol 2012; 14: 1037-1049.
23. Jacobson EL, Lange RA, Jacobson MK,. Pyridine nucleotide synthesis in 3T3 cells. J Cell Physiol 1979; 99: 417-425.
24. Lukasiak S, Breuhahn K, Schiller C, et al., Quantitative analysis of gene expression relative to 18S rRNA in carcinoma samples using the LightCycler instrument and a SYBR GreenI-based assay: determining FAT10 mRNA levels in hepatocellular carcinoma. Methods Mol Biol 2008; 429: 59-72.
25. Grimm MO, Haupenthal VJ, Rothhaar TL, et al., Effect of different phospholipids on alpha-secretase activity in the non-amyloidogenic pathway of Alzheimer's disease. Int J Mol Sci 2013; 14: 5879-5898.
26. Rothhaar TL, Grosgen S, Haupenthal VJ, et al., Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer's disease. ScientificWorldJournal 2012;2012: 141240.
27. Seibenhener ML, Wooten MW,. Isolation and culture of hippocampal neurons from prenatal mice. J Vis Exp 2012;(65).
28. Qin WP, Yang TL, Ho L, et al., Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem 2006; 281: 21745-21754.
29. Kellenberger E, Kuhn I, Schuber F, et al., Flavonoids as inhibitors of human CD38. Bioorg Med Chem Lett 2011; 21: 3939-3942.
30. Rogers J, Strohmeyer R, Kovelowski CJ, et al., Microglia and inflammatory mechanisms in the clearance of amyloid beta peptide. Glia 2002; 40: 260-269.
31. Savonenko A, Xu GM, Melnikova T, et al., Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities. Neurobiol Dis 2005; 18: 602-617.
32. Jankowsky JL, Melnikova T, Fadale DJ, et al., Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci 2005; 25: 5217-5224.
33. Selkoe DJ,. Alzheimer's disease is a synaptic failure. Science 2002; 298: 789-791.
34. Perez-Gonzalez R, Alvira-Botero MX, Robayo O, et al., Leptin gene therapy attenuates neuronal damages evoked by amyloid-beta and rescues memory deficits in APP/PS1 mice. Gene Ther 2014; 21: 298-308.
35. Berridge MJ,. Calcium hypothesis of Alzheimer's disease. Pflugers Archiv 2010; 459: 441-449.
36. Reyes-Harde M, Potter BV, Galione A, et al., Induction of hippocampal LTD requires nitric-oxide-stimulated PKG activity and Ca2+ release from cyclic ADP-ribose-sensitive stores. J Neurophysiol 1999; 82: 1569-1576.
37. Gong B, Pan Y, Vempati P, et al., Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-gamma coactivator 1alpha regulated beta-secretase 1 degradation and mitochondrial gene expression in Alzheimer's mouse models. Neurobiol Aging 2013; 34: 1581-1588.
38. Barbosa MT, Soares SM, Novak CM, et al., The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J 2007; 21: 3629-3639.
39. Wang J, Fivecoat H, Ho L, et al., The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim Biophys Acta 2010; 1804: 1690-1694.
40. Wu F, Schweizer C, Rudinskiy N, et al., Novel gamma-secretase inhibitors uncover a common nucleotide-binding site in JAK3, SIRT2, and PS1. FASEB J 2010; 24: 2464-2474.
41. Fukumoto H, Rosene DL, Moss MB, et al., Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol 2004; 164: 719-725.
42. Bateman RJ, Siemers ER, Mawuenyega KG, et al., A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009; 66: 48-54.
43. Siemers ER, Dean RA, Friedrich S, et al., Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin Neuropharmacol 2007; 30: 317-325.
44. Dovey HF, John V, Anderson JP, et al., Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem 2001; 76: 173-181.
45. Abramowski D, Wiederhold KH, Furrer U, et al., Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition. J Pharmacol Exp Ther 2008; 327: 411-424.
46. De Strooper B, Chavez Gutierrez L,. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. Annu Rev Pharmacol Toxicol 2015; 55: 419-437.